Immunotherapy for advanced gastric cancer

doi:10.5662/wjm.v13.i3.79

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 3

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4567)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-2) series.

Item

Count

PDF

WORD

HTML

2206

Figures (1-2)

266

Tables (1-2)

426

Sum=3035

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

159

Download

549

Sum=708

Publishing Process of This Article

Item

Count

Browse

218

Download

442

Sum=660

Jun 20, 2023 (publication date) through Nov 19, 2024

Times Cited of This Article

Times Cited (6)

Journal Information of This Article

Publication Name

World Journal of Methodology

ISSN

2222-0682

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Methodol. Jun 20, 2023; 13(3): 79-97
Published online Jun 20, 2023. doi: 10.5662/wjm.v13.i3.79

Full Size Figure Download Figure

Figure 2 Immune check point inhibitors for advanced gastric cancer treatment. CTLA4: Cytotoxic T-lymphocyte-associated protein 4; TCR: T-cell receptor; PD-1: Programmed cell death protein 1; PD-L1: Programmed cell death ligand-1; MCH: Melanin-concentrating hormone.

Citation: Leowattana W, Leowattana P, Leowattana T. Immunotherapy for advanced gastric cancer. World J Methodol 2023; 13(3): 79-97
URL: https://www.wjgnet.com/2222-0682/full/v13/i3/79.htm
DOI: https://dx.doi.org/10.5662/wjm.v13.i3.79